Most previous studies aimed at estimating the number of human T-cell leukemia virus type-1 (HTLV-1) carriers in endemic areas have been based on seroprevalence rates in blood donors; however, this may result in underestimation because of the healthy donor effect. People who have health problem do not donate blood. In the present study, the number of HTLV-1 carriers in Nagasaki City was estimated based on the seroprevalence rates in a hospital-based population from Nagasaki University Hospital. In accordance with previous reports, seroprevalence of HTLV-1 was higher in females, and year of birth-specific seroprevalence showed a significant annual decline in both genders (P for trend: <0.0001). The estimated number of HTLV-1 carriers in Nagasaki City was 36,983. The incidence of adult T-cell leukemia/lymphoma (ATLL) among HTLV-1 carriers was estimated using data from the Nagasaki Prefectural Cancer Registry. The estimated annual incidence of ATLL was 61 per 100,000 HTLV-1 carriers, and the crude lifetime risk of the development was 7.29% for males and 3.78% for females. There is a large pool of HTLV-1 carriers aged over 70 years, and a continuing development of cases of ATLL among the elderly is therefore expected.
1920 Poster Board I-943 Introduction: The prevalence of HTLV-1 is mostly evaluated by the age-specific seroprevalence in blood donors, and the results have been conventionally used to estimate the age-specific incidence of ATL in Japan. However, the results may be underestimated due to an age limit (16-69 yr) for donation, a healthy donor effect, and a birth cohort effect. Data concerning the birth-year specific incidence of ATL among HTLV-1 carriers other than blood donors are scarce. Methods: The study evaluated data of the anti-HTLV-1 antibody testing of 10,261 patients (males: 5,523, females: 4,737) who visited the Nagasaki University Hospital during 2000-2007 and data of 360 ATL cases (males: 188, females: 172) who were diagnosed in Nagasaki City (an endemic area in Japan) in a population-based Nagasaki Prefectural Cancer Registry (NPCR). To estimate birth-year specific incidence rates of ATL in population-based HTLV-1 carriers, we used the 2006 census population for Nagasaki City by applying the hospital-based seroprevalence data. Results: Of 10,261 patients, 1,392 (males: 653, females: 739) were HTLV-1 antibody positive. The overall HTLV-1 seroprevalence was 13.57% (95%CI: 12.90-14.23%). The seroprevalence was significantly higher in females than in males (15.60% vs. 11.82%, P<0.0001). The birth-year specific seroprevalence was 18.69% (before 1926), 17.83% (1927-1936), 15.91% (1937-1946), 13.80% (1947-1956), 9.19% (1957-1966), 4.07% (1967-1976), 2.07% (1977-1986), and 0% (after 1987) (a significantly declining trend: P <0.0001). The estimated annual number of HTLV-1 carriers by birth-year in Nagasaki city was 5257, 8093, 8151, 8083, 4434, 2180, 785, and 0, respectively. Finally, we estimated the annual incidence rate of ATLL per 100,000 HTLV-1 carriers by birth-year; 171 (before 1926), 86 (1927-1936), 41 (1937-1946), 32 (1947-1956), 11 (1957-1966), and 0 (after 1967). The crude lifetime risk of developing ATLL in HTLV-1 carriers was estimated to be 7.29% for males and 3.78% for females. Conclusions: The birth-year specific HTLV-1 seroprevalnces in the present study were approximately 50% higher than those previously reported in blood donors1 (for example: 6.22% in those born before 1950). Although it is possible that our results are over-estimated2, the present study suggests that there is still a large pool of elderly HTLV-1 carriers in this endemic area. Further studies are needed to investigate the mechanism of the development of ATL among HTLV-1 carriers for preventing the development. Reference: 1) Iwanaga M et al. Int J Hematol, 2009. 2) Arisawa K et al. Int J Cancer, 2000. Disclosures: No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.